Paris,11th May 2026 – New pathologies, AI potential, external growth: Sêmeia, the French leader in remote patient monitoring, has completed a €21m funding round with European funds, giving it the resources to achieve its ambitions.
Having achieved profitability and large-scale deployment of remote monitoring in nephrology, Sêmeia is now strengthening its capabilities to:
- expand its offering to healthcare professionals by addressing new pathologies and delivering innovative services for both care and clinical research;
- pursue its external growth strategy following two successful acquisitions.
“This funding round opens a new chapter in Sêmeia’s journey. It strengthens our teams’ ability to support healthcare professionals and patients. We are also delighted to welcome new partners who are fully aligned with our ambition to generate a concrete and lasting impact on the healthcare system.”
A LEADING SOLUTION FOR REMOTE MONITORING WITH PROVEN OUTCOMES
The growing prevalence of chronic diseases, which is expected to affect up to 16 million patients and account for 75% of the health budget in France alone by 2035, coupled with the ongoing shortage of healthcare professionals, challenges the entire health system. Remote patient monitoring is now recognized as a key driver to optimize care pathways, benefiting health professionals, patients, and the overall efficiency of the healthcare system.
With over 35,000 patients monitored across 500 healthcare facilities, the Toulouse-based company is the leading French solution for multi-pathology remote monitoring.
Its data-driven medical device, MedicWise, is already active in the fields of nephrology, transplantation, mental health, and cardiology, providing practitioners with automatic collection, structuring, and display of outpatient data as well as the generation of highly targeted alerts.
In nephrology, where Sêmeia is the go-to solution, remote patient monitoring has proven to offer both clinical and organisational benefits: a 26% reduction in patients’ hospitalisations and a 73% reduction in physicians’ time[1].
Almost a third of patients followed up by Sêmeia live in areas with limited access to healthcare, demonstrating its active contribution to reducing regional disparities in access to care.
SETTING A NEW CHAPTER: SETTLE MULTI-PATHOLOGY TELEMEDICINE AS A STANDARD FOR HEALTH PROFESSIONALS AND PATIENTS
Sêmeia is now focusing on the large-scale roll-out of remote patient monitoring products across multiple pathologies, such as mental health conditions like bipolar disorder and depression, type 2 diabetes, IBD, or chronic liver diseases.
The first medical studies have already revealed significant improvements when using MedicWise, such as a 50% reduction in suicide attempts and a 41% reduction in emergency hospitalisations of patients with bipolar disorder.
AN AMBITION TO SCALE UP TELEMONITORING AND CONSOLIDATE THE EUROPEAN E-HEALTH MARKET
With this new funding, Sêmeia aims to intensify its position as a leader within the European healthcare system.
Support the successful rollout of telemonitoring for new pathologies.
Semeia is planning to drive new medical studies with the support of clinical experts to validate the positive impact of telemonitoring in new pathologies ahead of its market entry. Some are already underway (e.g., in gastroenterology), with more to follow.
Strengthen investments in data-driven innovation through AI technologies for care and research.
Semeia is committed to integrating new AI-driven features to enhance software performance continuously and optimise the organisation of medical follow-up. This effort will also support the company’s contribution to over fifteen medical research projects conducted in partnership with clinical teams.
Confirm its position as a key player in the telemedicine market through partnerships and targeted acquisitions.
Sêmeia will pursue a strategy of partnerships and selective acquisitions to improve user experience and the integration of digital solutions into care pathways. After two strategic acquisitions – Optim’Care in 2022 and Healabs in 2025 – several new discussions are already in progress.
COMMITTED INVESTORS SUPPORTING HIGH-IMPACT MEDICAL INNOVATION
This fundraising brings together investors who are recognised for their commitment to technological innovation and impact-driven companies. These include the German fund Acton Capital, and French impact investment funds, Mutuelles Impact (a fund initiated by Mutualité Française and managed by XAnge in partnership with Impactivist), and Citizen Capital. Historical investors, Banque des Territoires (Groupe Caisse des Dépôts) – for which the operation fully aligns with the implementation of the "Santé et Grand âge" roadmap of the Caisse des Dépôts Group, committing €25 billion over a 5-year period - and Orange Ventures, have also renewed their commitment alongside Sêmeia.
“We are very happy to take an active part in the support of Sêmeia’s technical expertise and in its ambition to deliver high-impact digital health services. By leveraging innovative technologies, Sêmeia is supporting healthcare professionals and patients for better care while contributing to the efficiency and sustainability of the healthcare system”
“Sêmeia combines what rarely goes together in healthtech: clinical evidence, large-scale adoption, and profitability. Backing Pierre and his team is a natural fit for our impact thesis — supporting companies that deliver measurable value to patients, clinicians and the healthcare system alike.”
- About Sêmeia - Founded in 2017 in Toulouse, Sêmeia offers MedicWise, a platform for the automatic collection and processing of health data, providing an innovative approach to patient follow-up: both in consultation and remotely, without overburdening patients or care teams. Designed in collaboration with healthcare professionals, it combines medical expertise and data science to optimise care pathways, benefiting clinicians, patients, healthcare facilities and the health system as a whole. Our purpose? To help healthcare professionals more effectively support their patients living with chronic conditions.
- About XAnge - XAnge is a B Corp-certified early-stage investment fund with €800m under management and offices in Paris, Berlin and Brussels. The fund backs European founders aiming to transform everyday life through technology, investing between €1m and €15m from seed through Series C. XAnge is the venture capital brand of the Siparex group.
- About Mutuelles Impact - Created in 2020 at the initiative of Mutualité Française, managed by XAnge in partnership with Impactvist, Mutuelles Impact is the first impact fund dedicated to healthcare. Its objective is to invest in high-impact companies and support them in the areas of prevention, new care pathways, and medico-social services. With over €95m under management, the fund is backed by 64 French health insurers and 3 territorial actors (Banque des Territoires, Eurométropole de Strasbourg and e-Meuse santé).
[1] Christophe Mariat, Miriana Dinic, Damien Thibaudin, Nicolas Maillard, #2096 A randomized controlled study of telemonitoring in kidney transplantation: interim results of the Ap'TX trial, Nephrology Dialysis Transplantation, Volume 39, Issue Supplement_1, May 2024, gfae069–0092–2096, https://doi.org/10.1093/ndt/gfae069.092
